A metabolikus szindróma, diabetes mellitus és szkizofrénia komorbiditása: Elméleti és gyakorlati megfontolások

J. Réthelyi, Anna Dalal Sawalhe

Research output: Article

4 Citations (Scopus)

Abstract

Schizophrenia is a psychiatric disorder characterized by heterogeneous symptoms, affecting 0.8-1% of the population worldwide. It usually begins in early adulthood and demonstrates a chronic course. In recent years research interest has turned to the increased burden of somatic illness in schizophrenia, with special emphasis on metabolic syndrome and diabetes. In this article I review the theoretical and practical aspects of the comorbidity of schizophrenia with metabolic syndrome and diabetes mellitus. Epidemiological studies demonstrate the occurrence of metabolic syndrome between 22% and 66%, while the prevalence of diabetes is at least threefold compared to the non-psychiatric population in all age groups. Etiologically it is not clear to what extent these alterations are caused by direct genetic and biological effects in contrast to environmental factors. Among the latter the role of atypical antipsychotics should be emphasized. Clinical management of prediabetic conditions and diabetes in schizophrenia warrants the close cooperation of professionals working in the areas of psychiatry and diabetology. This cooperation should include close metabolic monitoring, lifestyle and dietary training, moreover careful modification and in some cases switching of antipsychotic medication. Persisting metabolic symptoms or diabetes require treatment with oral antidiabetics, fibrates, and statins. Orv. Hetil., 2011, 152, 505-511.

Original languageHungarian
Pages (from-to)505-511
Number of pages7
JournalOrvosi Hetilap
Volume152
Issue number13
DOIs
Publication statusPublished - márc. 1 2011

Fingerprint

Comorbidity
Schizophrenia
Antipsychotic Agents
Psychiatry
Fibric Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cost of Illness
Hypoglycemic Agents
Population
Life Style
Epidemiologic Studies
Diabetes Mellitus
Age Groups
Research
Therapeutics

Keywords

  • diabetes
  • insulin resistance
  • metabolic syndrome
  • schizophrenia
  • weight gain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{f214b33d8f734565b2f01ba188cb97ae,
title = "A metabolikus szindr{\'o}ma, diabetes mellitus {\'e}s szkizofr{\'e}nia komorbidit{\'a}sa: Elm{\'e}leti {\'e}s gyakorlati megfontol{\'a}sok",
abstract = "Schizophrenia is a psychiatric disorder characterized by heterogeneous symptoms, affecting 0.8-1{\%} of the population worldwide. It usually begins in early adulthood and demonstrates a chronic course. In recent years research interest has turned to the increased burden of somatic illness in schizophrenia, with special emphasis on metabolic syndrome and diabetes. In this article I review the theoretical and practical aspects of the comorbidity of schizophrenia with metabolic syndrome and diabetes mellitus. Epidemiological studies demonstrate the occurrence of metabolic syndrome between 22{\%} and 66{\%}, while the prevalence of diabetes is at least threefold compared to the non-psychiatric population in all age groups. Etiologically it is not clear to what extent these alterations are caused by direct genetic and biological effects in contrast to environmental factors. Among the latter the role of atypical antipsychotics should be emphasized. Clinical management of prediabetic conditions and diabetes in schizophrenia warrants the close cooperation of professionals working in the areas of psychiatry and diabetology. This cooperation should include close metabolic monitoring, lifestyle and dietary training, moreover careful modification and in some cases switching of antipsychotic medication. Persisting metabolic symptoms or diabetes require treatment with oral antidiabetics, fibrates, and statins. Orv. Hetil., 2011, 152, 505-511.",
keywords = "diabetes, insulin resistance, metabolic syndrome, schizophrenia, weight gain",
author = "J. R{\'e}thelyi and Sawalhe, {Anna Dalal}",
year = "2011",
month = "3",
day = "1",
doi = "10.1556/OH.2011.29079",
language = "Hungarian",
volume = "152",
pages = "505--511",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "13",

}

TY - JOUR

T1 - A metabolikus szindróma, diabetes mellitus és szkizofrénia komorbiditása

T2 - Elméleti és gyakorlati megfontolások

AU - Réthelyi, J.

AU - Sawalhe, Anna Dalal

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Schizophrenia is a psychiatric disorder characterized by heterogeneous symptoms, affecting 0.8-1% of the population worldwide. It usually begins in early adulthood and demonstrates a chronic course. In recent years research interest has turned to the increased burden of somatic illness in schizophrenia, with special emphasis on metabolic syndrome and diabetes. In this article I review the theoretical and practical aspects of the comorbidity of schizophrenia with metabolic syndrome and diabetes mellitus. Epidemiological studies demonstrate the occurrence of metabolic syndrome between 22% and 66%, while the prevalence of diabetes is at least threefold compared to the non-psychiatric population in all age groups. Etiologically it is not clear to what extent these alterations are caused by direct genetic and biological effects in contrast to environmental factors. Among the latter the role of atypical antipsychotics should be emphasized. Clinical management of prediabetic conditions and diabetes in schizophrenia warrants the close cooperation of professionals working in the areas of psychiatry and diabetology. This cooperation should include close metabolic monitoring, lifestyle and dietary training, moreover careful modification and in some cases switching of antipsychotic medication. Persisting metabolic symptoms or diabetes require treatment with oral antidiabetics, fibrates, and statins. Orv. Hetil., 2011, 152, 505-511.

AB - Schizophrenia is a psychiatric disorder characterized by heterogeneous symptoms, affecting 0.8-1% of the population worldwide. It usually begins in early adulthood and demonstrates a chronic course. In recent years research interest has turned to the increased burden of somatic illness in schizophrenia, with special emphasis on metabolic syndrome and diabetes. In this article I review the theoretical and practical aspects of the comorbidity of schizophrenia with metabolic syndrome and diabetes mellitus. Epidemiological studies demonstrate the occurrence of metabolic syndrome between 22% and 66%, while the prevalence of diabetes is at least threefold compared to the non-psychiatric population in all age groups. Etiologically it is not clear to what extent these alterations are caused by direct genetic and biological effects in contrast to environmental factors. Among the latter the role of atypical antipsychotics should be emphasized. Clinical management of prediabetic conditions and diabetes in schizophrenia warrants the close cooperation of professionals working in the areas of psychiatry and diabetology. This cooperation should include close metabolic monitoring, lifestyle and dietary training, moreover careful modification and in some cases switching of antipsychotic medication. Persisting metabolic symptoms or diabetes require treatment with oral antidiabetics, fibrates, and statins. Orv. Hetil., 2011, 152, 505-511.

KW - diabetes

KW - insulin resistance

KW - metabolic syndrome

KW - schizophrenia

KW - weight gain

UR - http://www.scopus.com/inward/record.url?scp=79952858524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952858524&partnerID=8YFLogxK

U2 - 10.1556/OH.2011.29079

DO - 10.1556/OH.2011.29079

M3 - Article

C2 - 21398211

AN - SCOPUS:79952858524

VL - 152

SP - 505

EP - 511

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 13

ER -